They include Sanofi/Regeneron's IL-4/IL-13 inhibitor Dupixent (dupilumab) and AZ's own IL-5 inhibitor Fasenra (benralizumab), which competes with GlaxoSmithKline's Nucala (mepolizumab) and Teva's ...

Cutting corners: Researchers at Imperial College London say an artificial intelligence-based science tool created by Google needed just 48 hours to solve a problem that took them roughly a decade ...

The landing page revealed the As Ever logo, which PEOPLE understands is a tribute to Prince Harry. The logo incorporates a palm tree as a nod to the Duke and Duchess’s home in California ...

Is it the smoothness of running shoes or the convenience of your favourite gym shorts? Or maybe those famous logos let you know at a glance which brand you’re dealing with. In athletic apparel, logos ...

Meghan Markle recently unveiled her rebranded lifestyle brand, As Ever, and its new logo is packed with subtle nods to her family and personal history. The design features a palm tree encased by ...

Sanofi and Regeneron’s Dupixent (dupilumab) has been accepted for priority review by the US Food and Drug Administration (FDA) to treat adults with bullous pemphigoid (BP). BP is a chronic and ...

Meghan's forthcoming lifestyle brand, As Ever, replaces American Riviera Orchard, and its logo features some symbolic details – one of which could be a tribute to Prince Harry's late grandmother ...

Like Queen Elizabeth, she loves horses and a great tiara moment. Meghan Markle's refreshed lifestyle brand has a logo with a meaningful symbol. On Feb. 18, the Duchess of Sussex announced that she ...

Just like the brand’s logo, the brand’s name is full of meaning, too. In an Instagram video, Meghan explained, “As Ever essentially means ‘as it’s always been,’ and if you’ve ...

Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid If approved, Dupixent would be the first and only targeted medicine to treat BP in the US; FDA ...

Regeneron Pharmaceuticals and Sanofi have won Food and Drug Administration priority review of their application seeking expanded approval of their blockbuster anti-inflammatory drug Dupixent for ...